Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Micro-ribonucleic acids and extracellular vesicles repertoire in the spent culture media is altered in women undergoing In Vitro Fertilization.

Abu-Halima M, Häusler S, Backes C, Fehlmann T, Staib C, Nestel S, Nazarenko I, Meese E, Keller A.

Sci Rep. 2017 Oct 19;7(1):13525. doi: 10.1038/s41598-017-13683-8.

2.

Global transcriptome sequencing identifies chlamydospore specific markers in Candida albicans and Candida dubliniensis.

Palige K, Linde J, Martin R, Böttcher B, Citiulo F, Sullivan DJ, Weber J, Staib C, Rupp S, Hube B, Morschhäuser J, Staib P.

PLoS One. 2013 Apr 15;8(4):e61940. doi: 10.1371/journal.pone.0061940. Print 2013.

3.

Factors supporting cysteine tolerance and sulfite production in Candida albicans.

Hennicke F, Grumbt M, Lermann U, Ueberschaar N, Palige K, Böttcher B, Jacobsen ID, Staib C, Morschhäuser J, Monod M, Hube B, Hertweck C, Staib P.

Eukaryot Cell. 2013 Apr;12(4):604-13. doi: 10.1128/EC.00336-12. Epub 2013 Feb 15.

4.

Dendritic cells: elegant arbiters in human reproduction.

Segerer SE, Staib C, Kaemmerer U, Frambach T, Honig A, Dietl J, Rieger L.

Curr Pharm Biotechnol. 2012 Jun;13(8):1378-84. Review.

PMID:
22339222
5.

Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha.

Backes S, Sperling KM, Zwilling J, Gasteiger G, Ludwig H, Kremmer E, Schwantes A, Staib C, Sutter G.

J Gen Virol. 2010 Feb;91(Pt 2):470-82. doi: 10.1099/vir.0.015347-0. Epub 2009 Oct 21.

PMID:
19846675
6.

The orthopoxvirus 68-kilodalton ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in nonpermissive human and murine cells.

Sperling KM, Schwantes A, Staib C, Schnierle BS, Sutter G.

J Virol. 2009 Jun;83(12):6029-38. doi: 10.1128/JVI.01628-08. Epub 2009 Apr 8.

7.

Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.

Di Lullo G, Soprana E, Panigada M, Palini A, Erfle V, Staib C, Sutter G, Siccardi AG.

J Virol Methods. 2009 Mar;156(1-2):37-43. doi: 10.1016/j.jviromet.2008.10.026. Epub 2008 Dec 10.

PMID:
19038289
8.

Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization.

Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G.

J Gene Med. 2008 Dec;10(12):1324-33. doi: 10.1002/jgm.1256.

PMID:
18816482
9.

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

Schulze K, Staib C, Schätzl HM, Ebensen T, Erfle V, Guzman CA.

Vaccine. 2008 Dec 2;26(51):6678-84. doi: 10.1016/j.vaccine.2008.09.006.

PMID:
18805454
10.

In vivo attenuation of recombinant murine gammaherpesvirus 68 (MHV-68) is due to the expression and immunogenicity but not to the insertion of foreign sequences.

El-Gogo S, Flach B, Staib C, Sutter G, Adler H.

Virology. 2008 Oct 25;380(2):322-7. doi: 10.1016/j.virol.2008.07.034. Epub 2008 Sep 5.

11.

The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.

Mamani-Matsuda M, Cosma A, Weller S, Faili A, Staib C, Garçon L, Hermine O, Beyne-Rauzy O, Fieschi C, Pers JO, Arakelyan N, Varet B, Sauvanet A, Berger A, Paye F, Andrieu JM, Michel M, Godeau B, Buffet P, Reynaud CA, Weill JC.

Blood. 2008 May 1;111(9):4653-9. doi: 10.1182/blood-2007-11-123844. Epub 2008 Mar 3.

12.

Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.

El-Gogo S, Staib C, Lasarte JJ, Sutter G, Adler H.

J Gene Med. 2008 Feb;10(2):177-86.

PMID:
18076128
13.

Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.

Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schätzl H, Busch DH, Sutter G, Goebel FD, Erfle V.

AIDS Res Hum Retroviruses. 2007 Jun;23(6):782-93.

PMID:
17604541
14.

Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.

El-Gogo S, Staib C, Meyr M, Erfle V, Sutter G, Adler H.

Vaccine. 2007 May 16;25(20):3934-45. Epub 2007 Mar 6.

PMID:
17433507
15.

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity.

Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-Pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan M, Whelan JA, Adams VC, Larrea E, Riezu JI, Lasarte JJ, Bartosch B, Cosset FL, Spaan WJ, Diepolder HM, Pape GR, Sutter G, Inchauspe G, Heeney JL.

Hepatology. 2007 Mar;45(3):602-13. Erratum in: Hepatology. 2007 Jun;45(6):1590. Adams, Victoria A [corrected to Adams, Victoria C]; Lasarte, Juan José [corrected to Lasarte, Juan J].

PMID:
17326154
16.

Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.

Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G.

J Gen Virol. 2006 Oct;87(Pt 10):2917-21.

PMID:
16963750
17.
18.

Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines.

Heit A, Schmitz F, O'Keeffe M, Staib C, Busch DH, Wagner H, Huster KM.

J Immunol. 2005 Apr 1;174(7):4373-80.

20.

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Drexler I, Staib C, Sutter G.

Curr Opin Biotechnol. 2004 Dec;15(6):506-12. Review.

PMID:
15560976
21.

Construction and isolation of recombinant MVA.

Staib C, Drexler I, Sutter G.

Methods Mol Biol. 2004;269:77-100. Review.

PMID:
15114009
22.

Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Cosma A, Bühler S, Nagaraj R, Staib C, Hammarin AL, Wahren B, Goebel FD, Erfle V, Sutter G.

Clin Diagn Lab Immunol. 2004 Mar;11(2):406-10.

23.

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Sutter G, Staib C.

Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. Review.

PMID:
14529359
24.

Live viral vectors: vaccinia virus.

Staib C, Sutter G.

Methods Mol Med. 2003;87:51-68. No abstract available.

PMID:
12958449
25.

Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Hornemann S, Harlin O, Staib C, Kisling S, Erfle V, Kaspers B, Häcker G, Sutter G.

J Virol. 2003 Aug;77(15):8394-407.

26.

Improved host range selection for recombinant modified vaccinia virus Ankara.

Staib C, Löwel M, Erfle V, Sutter G.

Biotechniques. 2003 Apr;34(4):694-6, 698, 700. No abstract available.

27.

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Ohlschläger P, Osen W, Dell K, Faath S, Garcea RL, Jochmus I, Müller M, Pawlita M, Schäfer K, Sehr P, Staib C, Sutter G, Gissmann L.

J Virol. 2003 Apr;77(8):4635-45.

28.

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

Drexler I, Staib C, Kastenmuller W, Stevanović S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22. Epub 2002 Dec 23.

29.

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P.

J Immunol. 2003 Jan 1;170(1):270-8.

30.

Full-length core sequence dependent complex-type glycosylation of hepatitis C virus E2 glycoprotein.

Zhu LX, Liu J, Li YC, Kong YY, Staib C, Sutter G, Wang Y, Li GD.

World J Gastroenterol. 2002 Jun;8(3):499-504.

31.
32.

Transient host range selection for genetic engineering of modified vaccinia virus Ankara.

Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G.

Biotechniques. 2000 Jun;28(6):1137-42, 1144-6, 1148.

33.

Identification and characterization of a mouse homolog to yeast Cdc6p.

Berger C, Strub A, Staib C, Lepke M, Zisimopoulou P, Hoehn K, Nanda I, Schmid M, Grummt F.

Cytogenet Cell Genet. 1999;86(3-4):307-16.

PMID:
10575231
34.

Identification, characterization and chromosomal localization of the cognate human and murine DBF4 genes.

Lepke M, Pütter V, Staib C, Kneissl M, Berger C, Hoehn K, Nanda I, Schmid M, Grummt F.

Mol Gen Genet. 1999 Sep;262(2):220-9.

PMID:
10517317
35.
36.

Mouse homolog of the yeast origin recognition complex subunit ORC1 and chromosomal localization of the cognate mouse gene Orc1.

Zisimopoulou P, Staib C, Nanda I, Schmid M, Grummt F.

Mol Gen Genet. 1998 Nov;260(2-3):295-9.

PMID:
9862484
37.
38.

Mapping replication origins by nascent DNA strand length.

Staib C, Grummt F.

Methods. 1997 Nov;13(3):293-300. Review.

PMID:
9441855
39.

Repression of interleukin-2 and interleukin-4 promoters by tumor suppressor protein p53.

Pesch J, Brehm U, Staib C, Grummt F.

J Interferon Cytokine Res. 1996 Aug;16(8):595-600.

PMID:
8877730
40.

p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen.

Staib C, Pesch J, Gerwig R, Gerber JK, Brehm U, Stangl A, Grummt F.

Virology. 1996 May 1;219(1):237-46.

Supplemental Content

Support Center